Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout.

Introduction: Hyperuricemia is a common metabolic disease, which is a risk factor for gouty arthritis and ureteral stones and may also lead to cardiovascular and chronic kidney disease (CDK). Therefore, hyperuricemia should be treated early. Xanthine oxidase inhibitors (XOIs) and uricosuric agents (UAs), which target uric acid, are two types of medications that are used to treat gout and hyperuricemia.

The effects and underlying mechanisms of medicine and food homologous flowers on the prevention and treatment of related diseases.

The theory of medicine and food homology has a long history in China. Numerous traditional Chinese medicinal could be used as both medicine and food. Many flower medicinal materials also belong to the homology of medicine and food, such as Chrysanthemum morifolium, Lonicera japonica, Crocus sativus, and Lonicera macranthoides.

Preparation of an isorhamnetin phospholipid complex for improving solubility and anti-hyperuricemia activity.

To improve the solubility and anti-hyperuricemia activity of the insoluble natural flavonoid isorhamnetin (ISO), an isorhamnetin phospholipid complex (ISO-PC) was prepared. ISO-PC was prepared through solvent evaporation and its prescription process was optimized. The formation of ISO-PC was verified via multiple characterization methods.